The Hymenolepis diminuta–Golden Hamster (Mesocricetus auratus) Model for the Evaluation of Gastrointestinal Anticestode Activity

A novel laboratory anticestode assay was developed using Hymenolepis diminuta in the hamster. The commercial anticestode compounds, praziquantel, bunamidine, and niclosamide were active against patent infections of Hymenolepis diminuta in golden hamsters (Mesocricetus auratus) when given orally at 3.125, 100, and 200 mg/kg, respectively. The gastrointestinal nematode anthelmintics, cambendazole and mebendazole, were active at 50 mg/kg. Rafoxanide (fasciolicide) was active at 25 mg/kg, the lowest level tested. The coccidiostat, nicarbazin, was active at experimental levels (800 mg/kg and up). The anthelmintic-ectoparasiticide (endectocide), ivermectin, was inactive against the tapeworm at 0.5 mg/kg, as expected.

Human lagochilascariasis treated successfully with ivermectin: a case report

A 15 year old male patient was diagnosed as being infected with the nematode Lagochilascaris minor, presenting as abscesses over the left mastoid region, and invading the temporal bone, mastoid sinuses and possibly the CNS. Surgical drainage and administration of cambendazole and levamisole led to improvement, followed by an early relapse and poor tolerance to the antihelminthic drugs. Repeated doses of ivermectin (an animal preparation) were used for the first time to treat this condition and resulted in complete remission of signs of infection, maintained for 15 months after the end of drug therapy, indicating cure of the disease.

The efficacy of anthelmintics against Thysaniezia giardi in South Africa

Two field cases of apparent inefficacy of albendazole against cestodes in lambs were investigated. In both farms Thysaniezia giardi was identified and 2 critical controlled trials were conducted to determine the efficacy of 5 anthelmintics against T. giardi. Albendazole dosed at 3,8 mg/kg or 7,6 mg/kg live mass, mebendazole at 15 mg/kg were totally ineffective against T. giardi. Treatment with resorantel at 65 mg/kg or niclosamide at 50 mg/kg however, caused expulsion of the strobilae within 16--24 hours after treatment and at autopsy, lambs were free of scoleces of T. giardi.

A critical efficacy test of cambendazole in equids: the use of the geometric means to assess efficacy

The anthelmintic efficacy of a 44.5% paste formulation of cambendazole was evaluated in a critical trial performed on 5 horses and a donkey. A dosage of 20 mg/kg showed reduction of mean parasite burdens as follows: Strongylinae greater than 99%; Cyathostominae 94%; immature and adult Oxyuris equi 89 and greater than 99%; Probstmayria vivipara greater than 99% and Habronema muscae 97%. Parascaris equorum and Anoplocephala perfoliata were present in small numbers in individual animals only, and while all were removed by treatment, the small numbers did not justify calculation of a percentage efficacy for these 2 parasites.

Efficacy studies with three formulations of cambendazole in horses

Treatment with 3 formulations of cambendazole (paste, pellets, and suspension) was compared with thiabendazole treatment in 181 Quarter Horses (females and intact and altered males) of different ages in 2 experiments. The mean output of strongyle eggs, as measured by eggs per gram of feces (epg), was reduced by at least 95% by the 3 formulations of cambendazole compared with pretreatment epg and epg in simultaneously nonmedicated horses. Eggs of Parascaris equorum were seen in 19 of the younger horses in experiment I. Parascaris eggs were not seen in postmedication fecal samples from 14 horses treated wtih cambendazole. Of the 5 horses treated with thiabendazole, 2 had postmedication Parascaris egg counts.

Effect of parenterally injected benzimidazole compounds on Echinococcus multilocularis and Taenia crassiceps metacestodes in laboratory animals

In mice infected with metacestodes of Taenia crassiceps, the following compounds were at least partially effective when injected intraperitoneally at the dosage indicated: cambendazole (500 mg/kg), mebendazole (6.25 mg/kg), oxibendazole (500 mg/kg), 5-benzamido-2(4-thiazolyl)benzimidazole (500 mg/kg), 2-carboethoxyamino benzimidazole (125 mg/kg), and 2-carbomethoxyamino benzimidazole (500 mg/kg). The following were inactive at the dosage indicated: parbendazole (500 mg/kg), thiabendazole (1,000 mg/kg), and fenbendazole (1,000 mg/kg). Mebendazole, which showed some activity at 6.25 mg/kg, was highly active as a single intraperitoneal dose at 25 mg/kg. When injected subcutaneously, mebendazole was much less active than when given intraperitoneally. In mice infected with metacestodes of Echinococcus multilocularis, intraperitoneal injection of mebendazole at 75 to 150 mg/kg, daily for 3 days, was highly effective (95 to 100% reduction in cyst mass). In contrast, oral administration at 1,000 mg/kg, daily for 3 days, was only partially effective. The drug was also effective when given intraperitoneally to infected cotton rats. A water-soluble benzimidazole, carboxymethyleneamino cambendazole, was approximately 50% effective in mice when injected daily for 3 days at a dosage of 75 or 150 mg/kg. The results suggest that, in metacestode infections of medical importance, it may be possible to kill the parasite by delivering a drug to its immediate vicinity, and so to reduce the required dosage with respect to the host.